ivonescimab Enhances Lung Survival
This is a news story, published by Investor's Business Daily, that relates primarily to Daina Graybosch news.
Daina Graybosch news
For more Daina Graybosch news, you can click here:
more Daina Graybosch newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsInvestor's Business Daily news
For more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Summit Therapeutics shares. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Cell Therapy Market news, BioNTech Stock Rides news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
BioNTech stockInvestor's Business Daily
•Health
Health
BioNTech Surges On Summit's Coattails. Can They Rival Merck?

83% Informative
Summit Therapeutics' drug, ivonescimab, works by blocking proteins called PD-1 and VEGF .
Leerink Partners analyst Daina Graybosch says the results have a highly promising readthrough for BioNTech stock.
Merck is also working on a drug that simultaneously blocks the proteins.
In the next study, Summit and Akeso plan to enroll patients with squamous and non-squamous forms of cancer.
VR Score
87
Informative language
90
Neutral language
42
Article tone
formal
Language
English
Language complexity
44
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links
Small business owner?